These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 29254769)

  • 21. Short term results of neoadjuvant chemoradiotherapy with fluoropyrimidine alone or in combination with oxaliplatin in locally advanced rectal cancer: a meta analysis.
    An X; Lin X; Wang FH; Goodman K; Cai PQ; Kong LH; Fang YJ; Gao YH; Lin JZ; Wan DS; Pan ZZ; Ding PR
    Eur J Cancer; 2013 Mar; 49(4):843-51. PubMed ID: 23063351
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predicting pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review.
    Ryan JE; Warrier SK; Lynch AC; Ramsay RG; Phillips WA; Heriot AG
    Colorectal Dis; 2016 Mar; 18(3):234-46. PubMed ID: 26531759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.
    Wong SJ; Moughan J; Meropol NJ; Anne PR; Kachnic LA; Rashid A; Watson JC; Mitchell EP; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):116-23. PubMed ID: 25446610
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of neoadjuvant intensity-modulated radiotherapy with concurrent capecitabine for locally advanced rectal cancer.
    Wang L; Li ZY; Li ZW; Li YH; Sun YS; Ji JF; Gu J; Cai Y
    Dis Colon Rectum; 2015 Feb; 58(2):186-92. PubMed ID: 25585076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oxaliplatin/fluorouracil-based adjuvant chemotherapy for locally advanced rectal cancer after neoadjuvant chemoradiotherapy and surgery: a systematic review and meta-analysis of randomized controlled trials.
    Zhao L; Liu R; Zhang Z; Li T; Li F; Liu H; Li G
    Colorectal Dis; 2016 Aug; 18(8):763-72. PubMed ID: 27169752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: Impact of postirradiated pathologic downstaging on local recurrence and survival.
    Kim NK; Baik SH; Seong JS; Kim H; Roh JK; Lee KY; Sohn SK; Cho CH
    Ann Surg; 2006 Dec; 244(6):1024-30. PubMed ID: 17122629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Total Neoadjuvant Therapy in Rectal Cancer: A Systematic Review and Meta-analysis of Treatment Outcomes.
    Petrelli F; Trevisan F; Cabiddu M; Sgroi G; Bruschieri L; Rausa E; Ghidini M; Turati L
    Ann Surg; 2020 Mar; 271(3):440-448. PubMed ID: 31318794
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial.
    Garcia-Aguilar J; Renfro LA; Chow OS; Shi Q; Carrero XW; Lynn PB; Thomas CR; Chan E; Cataldo PA; Marcet JE; Medich DS; Johnson CS; Oommen SC; Wolff BG; Pigazzi A; McNevin SM; Pons RK; Bleday R
    Lancet Oncol; 2015 Nov; 16(15):1537-1546. PubMed ID: 26474521
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
    Garcia-Aguilar J; Chow OS; Smith DD; Marcet JE; Cataldo PA; Varma MG; Kumar AS; Oommen S; Coutsoftides T; Hunt SR; Stamos MJ; Ternent CA; Herzig DO; Fichera A; Polite BN; Dietz DW; Patil S; Avila K;
    Lancet Oncol; 2015 Aug; 16(8):957-66. PubMed ID: 26187751
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Addition of platinum derivatives to neoadjuvant single-agent fluoropyrimidine chemoradiotherapy in patients with stage II/III rectal cancer: protocol for a systematic review and meta-analysis (PROSPERO CRD42017073064).
    Hüttner FJ; Probst P; Kalkum E; Hackbusch M; Jensen K; Ulrich A; Büchler MW; Diener MK
    Syst Rev; 2018 Jan; 7(1):11. PubMed ID: 29357929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved Metastasis- and Disease-Free Survival With Preoperative Sequential Short-Course Radiation Therapy and FOLFOX Chemotherapy for Rectal Cancer Compared With Neoadjuvant Long-Course Chemoradiotherapy: Results of a Matched Pair Analysis.
    Markovina S; Youssef F; Roy A; Aggarwal S; Khwaja S; DeWees T; Tan B; Hunt S; Myerson RJ; Chang DT; Parikh PJ; Olsen JR
    Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):417-426. PubMed ID: 28871992
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short-course Versus Long-course Preoperative Radiotherapy plus Delayed Surgery in the Treatment of Rectal Cancer: a Meta-analysis.
    Liu SX; Zhou ZR; Chen LX; Yang YJ; Hu ZD; Zhang TS
    Asian Pac J Cancer Prev; 2015; 16(14):5755-62. PubMed ID: 26320447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Toward the non-surgical management of locally advanced rectal cancer.
    Dewdney A; Cunningham D
    Curr Oncol Rep; 2012 Jun; 14(3):267-76. PubMed ID: 22460631
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of chemotherapy in localized and locally advanced rectal cancer: A systematic revision.
    Roselló S; Papaccio F; Roda D; Tarazona N; Cervantes A
    Cancer Treat Rev; 2018 Feb; 63():156-171. PubMed ID: 29407455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CEA - a predictor for pathologic complete response after neoadjuvant therapy for rectal cancer.
    Wallin U; Rothenberger D; Lowry A; Luepker R; Mellgren A
    Dis Colon Rectum; 2013 Jul; 56(7):859-68. PubMed ID: 23739192
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RandomizEd controlled trial for pre-operAtive dose-escaLation BOOST in locally advanced rectal cancer (RECTAL BOOST study): study protocol for a randomized controlled trial.
    Burbach JP; Verkooijen HM; Intven M; Kleijnen JP; Bosman ME; Raaymakers BW; van Grevenstein WM; Koopman M; Seravalli E; van Asselen B; Reerink O
    Trials; 2015 Feb; 16():58. PubMed ID: 25888548
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of radiotherapy boost on pathological complete response in patients with locally advanced rectal cancer: a systematic review and meta-analysis.
    Burbach JP; den Harder AM; Intven M; van Vulpen M; Verkooijen HM; Reerink O
    Radiother Oncol; 2014 Oct; 113(1):1-9. PubMed ID: 25281582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study.
    Fernández-Martos C; Pericay C; Aparicio J; Salud A; Safont M; Massuti B; Vera R; Escudero P; Maurel J; Marcuello E; Mengual JL; Saigi E; Estevan R; Mira M; Polo S; Hernandez A; Gallen M; Arias F; Serra J; Alonso V
    J Clin Oncol; 2010 Feb; 28(5):859-65. PubMed ID: 20065174
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant Treatment for Locally Advanced Rectal Cancer: New Concepts in Clinical Trial Design.
    Rana N; Chakravarthy AB; Kachnic LA
    Curr Treat Options Oncol; 2017 Feb; 18(2):13. PubMed ID: 28281215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant long-course chemoradiation remains strongly favored over short-course radiotherapy by radiation oncologists in the United States.
    Mowery YM; Salama JK; Zafar SY; Moore HG; Willett CG; Czito BG; Hopkins MB; Palta M
    Cancer; 2017 Apr; 123(8):1434-1441. PubMed ID: 27984651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.